Department of Chemistry Archives
Study reveals need for matching targeted therapies with EGFR subtypes
Jul. 28, 2022—A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
Personalized Structural Biology aids cancer treatment decisions
Apr. 8, 2021—Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.
Mar. 28, 2019—Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.
Designing antibodies to fight the flu
Jan. 31, 2019—Vanderbilt investigators said their work shows that computational design can improve the ability of naturally occurring antibodies to recognize different flu strains and may hasten the development of more effective flu therapies and vaccines.
DNA’s on/off switch
Jan. 17, 2019—DNA-binding “switches” represent a fundamentally new method of communication between DNA-processing enzymes, Vanderbilt researchers propose.
New view of the heartbeat
Apr. 6, 2018—Structural views of the proteins that regulate the heartbeat may help improve existing treatments for cardiac arrhythmias.
Transcription factor evolution
Aug. 11, 2016—Vanderbilt researchers have discovered a novel model of evolution for factors that control gene expression.
VU investigators use magnetism to help isolate malaria biomarker
Jan. 21, 2016—Vanderbilt investigators have developed a way to detect malaria that is faster and more sensitive than current clinical methods — a development that has the potential to make malaria detection significantly less expensive and more stable.
Chazin honored with international biophysics award
Oct. 22, 2015—Walter Chazin, Ph.D., director of the Vanderbilt Center for Structural Biology, is a recipient of a 2016 Fellow of the Biophysical Society award.
The yin and yang of COX-2
Oct. 2, 2015—New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs.
Collaboration seeks to develop new therapies for bone, other diseases
Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.
Framework for studying cell responses
Aug. 26, 2015—Vanderbilt investigators have developed a framework for studying cellular responses that could be used to identify the agents driving a range of biological processes in health and disease.